OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology, announces that results of its Phase 1 clinical study of Betalutin™ in patients with relapsed CD37+ Non-Hodgkin Lymphoma (NHL) will be presented at the International Conference on Malignant Lymphoma (13-ICML) that will take place on June 17 -20 in Lugano, Switzerland. Data and analysis will be presented in a post